InMed Pharmaceuticals Inc (INM)

[Vinpat]

By my estimation, Nemus is about 2 years ahead of InMed in glaucoma and their other drug candidate is about a year ahead of their glaucoma candidate. In comparison, the differences seem to be that Nemus already has several patents, they've proven they can make their leading drug to FDA standards and are working on fast tracking it to approval. They are now working on proving they can make their glaucoma drug.

InMed has no patents yet that we know of and it will take them 2 years to prove they can even make their EB drug.

Nemus has 1/4 of the outstanding shares and their market cap is 4 times less than InMed's. It seems to me that should be flip flopped. I'm waiting to see if InMed has patents and trying to figure out what they have before I pull the trigger and buy. Everyone is doing biosynthesis now so not sure if InMed has anything there either.